Reduced acetylation of α-tubulin correlates with axonal transport defects in Alzheimer’s and Huntington’s disease patients [66] and treatment with an HDAC inhibitor was shown to rescue vesicular transport in a Huntington’s disease model [86]. This evidence concerns the gene HDAC9 and juvenile Huntington disease.